Heartlab technology used to assess the safety and efficacy of drug-eluting stent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Heartlab Inc.'s CardioNow technology has been selected by Icon Interventional Systems Inc. to advance the sharing, tracking and analysis of angiograms and intravascular ultrasound (IVUS) studies for the company's Destiny I clinical trial.

The Destiny I trial is a multi-center study assessing the safety and efficacy of Icon's drug-eluting stent. Investigator sites in New Zealand and Australia will utilize Heartlab's CardioNow study sharing software to electronically transfer complete DICOM angiographic and IVUS studies to The University of Florida cardiovascular imaging core laboratory.

Images received electronically at Florida's laboratory will be analyzed at a CardioNow workstation by clinicians trained in performing computerized quantitative coronary angiography (QCA) and ultrasound (QCU).